HMMR and myelodysplastic syndrome: In a phase I clinical study, 10 patients suffering from AML, myelodysplastic syndrome, or multiple myeloma who possessed cancer cells expressing HLA-A2 and RHAMM were vaccinated with the RHAMM peptide R3.